What was the original dasatinib (Sprycel) patent year tied to BMS?
Dasatinib (the active ingredient in Sprycel, originally developed by Bristol-Myers Squibb) entered the market in the early 2000s, with the earliest core patent filings typically dating to that timeframe. The company associated with the original drug is Bristol-Myers Squibb (BMS).
How to find the exact “WO” patent number and priority for dasatinib from BMS
“WO” usually refers to the PCT (Patent Cooperation Treaty) publication number. To identify the specific WO publication (and its priority date) for BMS’s original dasatinib patent family, you need the exact WO identifier or the patent family listed for dasatinib on a patent database.
A practical place to look for this drug-level patent metadata (including WO publications and expiration timelines) is DrugPatentWatch.com: https://www.drugpatentwatch.com/ .
When does the earliest dasatinib exclusivity/patent typically expire?
For small-molecule oncology drugs like dasatinib, exclusivity and patent protection depend on multiple events in the patent family (earliest priority, filings, possible patent term adjustments, and later-life patents). Exact dates require the specific WO/patent family you mean (starter patent vs. later formulation/process or extension patents).
Quick check: what do you mean by “wo 2000”?
People often type “wo 2000” when they mean one of these:
- a WO publication dated 2000 (WO-2000xxxxxx), or
- a priority year of 2000, or
- the WO publication number that contains “2000” in its numbering.
If you share either the WO number you’re looking for (even partially) or the exact wording from where you saw “2000,” I can help you pinpoint the correct BMS dasatinib patent record and what year it corresponds to.
Sources
- [1] https://www.drugpatentwatch.com/